U.S. Markets open in 7 hrs 27 mins

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.67-0.23 (-1.78%)
At close: 04:00PM EDT
12.80 +0.13 (+1.03%)
After hours: 07:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.90
Bid12.66 x 800
Ask12.68 x 800
Day's Range12.08 - 13.14
52 Week Range7.55 - 40.64
Avg. Volume2,984,026
Market Cap417.469M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.47
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
  • Zacks

    What Makes Nkarta, Inc. (NKTX) a New Buy Stock

    Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Zacks

    Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

    SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of David R. Shook, MD, as Vice President, Clinical Development. Dr. Shook is a practicing pediatric hematologist, oncologist, and transplanter, and an early pioneer of natural killer (NK) cell therapy. He currently directs Nkarta’s co-lead clinical programs, N